CorFlow Therapeutics closed $44M Series B round

CorFlow Therapeutics AG raised €44 million in a Series B funding round. The round was co-led by Broadview Ventures and Panakes Partners, with participation from 415 Capital, Merieux Equity Partners, Laerdal Million Lives Fund, Wellington Partners, M&L Investments, Unorthodox Ventures, KOFA Healthcare, and Monte Carlo Capital.

CorFlow Therapeutics is developing the CoFI™ (Controlled Flow Infusion) system, a technology designed for the diagnostic assessment of coronary microcirculation immediately following stenting procedures and to enable the localized delivery of therapeutic agents. The company plans to use the funds to support an international pivotal trial (MOCA II) to diagnose Microvascular Obstruction (MVO) and a randomized controlled trial to evaluate therapeutic treatments for MVO through the CoFI system, with the goal of gaining US market clearance.